Implications loom large in human gene patent case before US Supreme Court (w/ video)

April 12, 2013

A human gene patenting case before the U.S. Supreme Court next week could have major implications for biotechnology research and the public interest in the nation's patent system, according to a University of Michigan expert.

Shobita Parthasarathy, associate professor at the Ford School of Public Policy, whose expert declaration on behalf of the plaintiffs was heavily cited by the district court that initially reviewed the case, says that major issues at stake include the basic question of whether are considered products of nature.

This video is not supported by your browser at this time.

"If they are, then according to the U.S. law, they can't be patented," she said. "In addition, there are major policy issues at stake. As the patent system has grown, it has become clear that it has mixed results for innovation, for society, for our values and for the economy."

The case began in 2009 when a coalition of scientists, physicians and patient advocacy groups represented by the filed suit against biotech company Myriad Genetics and the U.S. , challenging the patentability of genes linked to breast and ovarian cancer.

These groups alleged that Myriad's patents are invalid under Supreme Court precedent because they are "products of nature" and that they limit patient access to testing, increase health care costs, jeopardize testing quality, interfere with and privatize what once were public goods.

"In the breast cancer case, for example, a gene patent allows one company to control all genetic testing for in the United States," Parthasarathy said.

"What I hope is that we've started an ongoing discussion about how the serves the public interest because this is only one out of many controversies that are going on regarding patents on life-forms, patents on essential medicines and patents on information and communication technologies like the iPad."

The Supreme Court is expected to hear the case on April 15. Parthasarathy expects to attend and is available for media interviews before or after the session.

Explore further: US judge strikes down patent on cancer genes

Related Stories

US judge strikes down patent on cancer genes

March 29, 2010

(AP) -- In a ruling with potentially far-reaching implications for the patenting of human genes, a judge on Monday struck down a company's patents on two genes linked to an increased risk of breast and ovarian cancer.

US court to decide if human genes can be patented

November 30, 2012

The Supreme Court announced Friday it will decide whether companies can patent human genes, a decision that could reshape medical research in the United States and the fight against diseases like breast and ovarian cancer.

Recommended for you

Most EU nations seek to bar GM crops

October 4, 2015

Nineteen of the 28 EU member states have applied to keep genetically modified crops out of all or part of their territory, the bloc's executive arm said Sunday, the deadline for opting out of new European legislation on GM ...

Trade in invasive plants is blossoming

October 3, 2015

Every day, hundreds of different plant species—many of them listed as invasive—are traded online worldwide on auction platforms. This exacerbates the problem of uncontrollable biological invasions.

Ancestral background can be determined by fingerprints

September 28, 2015

A proof-of-concept study finds that it is possible to identify an individual's ancestral background based on his or her fingerprint characteristics – a discovery with significant applications for law enforcement and anthropological ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.